Amneal Pharmaceuticals, Inc.
HealthcareNASDAQ:AMRX · NASDAQ Global Select
-$0.14 today
Vol 2.24M · Avg 1.74M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $72.1M +197.5% | -$73.9M -51.6% | -$48.7M +80.9% | -$254.8M -2498.2% | $10.6M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $223.6M -5.3% | $236.2M +3.0% | $229.4M -4.5% | $240.2M +2.9% | $233.4M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $32.0M +15.1% | $27.8M +3.5% | $26.8M -15.8% | $31.8M | $0 | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$204.5M -4927.4% | -$4.1M +91.4% | -$47.2M +21.3% | -$59.9M +55.1% | -$133.6M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$120.6M +25.6% | -$162.2M -228.9% | $125.8M +259.1% | -$79.1M -384.8% | -$16.3M | $592.6M | $1.3B | $626.2M |
| Inventory | -$87.0M +33.3% | -$130.5M -3.4% | -$126.2M -23.2% | -$102.4M -108.9% | -$49.0M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $21.3M -90.9% | $235.1M +349.0% | -$94.4M -186.2% | $109.6M +349.4% | -$43.9M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$18.2M -134.1% | $53.5M +12.3% | $47.6M +298.6% | $12.0M +149.1% | -$24.3M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $216.9M +98.9% | $109.1M -41.1% | $185.3M +71.8% | $107.8M -17.9% | $131.4M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $340.0M +15.2% | $295.1M -14.6% | $345.6M +430.8% | $65.1M -73.1% | $241.8M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$70.1M +6.6% | -$75.0M -8.4% | -$69.2M +23.6% | -$90.6M -89.8% | -$47.7M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 -100.0% | $12.0M | $0 +100.0% | -$84.7M +40.1% | -$141.5M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$42.2M -188.1% | -$14.7M +34.6% | -$22.4M +45.1% | -$40.8M -1170.6% | -$3.2M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$112.3M -78.2% | -$63.0M +9.0% | -$69.2M +60.3% | -$174.3M +10.2% | -$194.2M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $26.3M +114.2% | -$185.1M -917.2% | $22.7M +159.2% | -$38.3M +51.7% | -$79.2M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $2.0M | $0 | $0 | $0 -100.0% | $853.0K | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$59.8M -124.0% | -$26.7M +88.7% | -$235.2M -244.2% | -$68.3M -14.3% | -$59.8M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$31.5M +85.1% | -$211.8M +0.4% | -$212.6M -99.4% | -$106.6M +22.8% | -$138.1M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | -$1.7M -68.2% | -$999.0K -1636.9% | $65.0K +101.1% | -$5.7M -5671.6% | $102.0K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $194.5M +907.2% | $19.3M -69.8% | $63.9M +128.8% | -$221.5M -145.1% | -$90.4M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $269.9M +22.6% | $220.1M -20.4% | $276.4M +1184.1% | -$25.5M -113.1% | $194.1M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Lantheus Holdings, Inc.
NASDAQ:LNTH
$6.80B
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
$4.99B
Indivior Pharmaceuticals Inc
NASDAQ:INDV
$4.80B
Envista Holdings Corp
NYSE:NVST
$4.00B
Telix Pharmaceuticals Limited
NASDAQ:TLX
$3.24B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.58B
Bausch Health Companies Inc.
NYSE:BHC
$1.89B
Perrigo Company plc
NYSE:PRGO
$1.52B
SEC Filings
Recent regulatory filings
No filings found.
Does AMRX generate free cash flow?
Amneal Pharmaceuticals, Inc. (AMRX) generated $269.93M of free cash flow in fiscal 2025.
How much operating cash flow does AMRX produce?
Operating cash flow was $339.99M, before capital expenditures of $70.06M.
Explore More
Continue the stock analysis
Jump to another research area for this company.